Different patterns of SIGLEC-9-Mediated neutrophil death responses in septic shock

Shock

Volumn 32, Issue 4, 2009, Pages 386-392

  Von Gunten, Stephan ^a   Jakob, Stephan M ^b   Geering, Barbara ^a   Takala, Jukka ^b   Simon, Hans Uwe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biomarker; Cell death; Lectins; Multiorgan failure; Neutrophils; Sepsis; Septic shock; Siglec 9; Siglecs

Indexed keywords

LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 9; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN CELL; INTENSIVE CARE UNIT; MALE; NEUTROPHIL; SEPTIC SHOCK; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL DEATH; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; INTENSIVE CARE UNITS; LECTINS; NEUTROPHILS; SHOCK, SEPTIC;

EID: 70349694527     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181a1bc98     Document Type: Article

References (49)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med 31:1250-1256, 2003.
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
4. Marshall JC: Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2:391-405, 2003.
5. Arcaroli J, Fessler MB, Abraham E: Genetic polymorphisms and sepsis. Shock 24:300-312, 2005.
6. Ulloa L, Tracey KJ: The "cytokine profile": a code for sepsis. Trends Mol Med 11:56-63, 2005.
7. Imahara SD, O'Keefe GE: Genetic determinants of the inflammatory response. Curr Opin Crit Care 10:318-324, 2004.
8. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D, Fisher CJ Jr, Faist E, Reinhart K: Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 31:1560-1567, 2003.
9. Marshall JC: Biomarkers of sepsis. Curr Infect Dis Rep 8:351-357, 2006.
10. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6:813-822, 2006.
11. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27:1230-1251, 1999.
12. Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A: Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 78:325-337, 2005.
13. Volk HD, Reinke P, Döcke WD: Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 74:162-177, 2000.
14. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125-1128, 1996.
15. Pinsky MR: Dysregulation of the immune response in severe sepsis. Am J Med Sci 328:220-229, 2004.
16. Oberholzer A, Oberholzer C, Moldawer LL: Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16:83-96, 2001.
17. Savill J, Fadok V: Corpse clearance defines the meaning of cell death. Nature 407:784-788, 2000.
18. Albert ML: Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 4:223-231, 2004.
19. Hotchkiss RS, Tinsley KW, Swanson PE, et al.: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166:6952-6963, 2001.
20. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, Wagner TH, Cobb JP, Coopersmith C, Karl IE: Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 168:2493-2500, 2002.
21. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA: Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 174:3765-3772, 2005.
22. Toti P, De FC, Occhini R, Schuerfeld K, Stumpo M, Epistolato MC, Vatti R, Buonocore G: Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol 122:765-771, 2004.
23. Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF: Neutrophils in development of multiple organ failure in sepsis. Lancet 368:157-169, 2006.
24. Marshall JC: Neutrophils in the pathogenesis of sepsis. Crit Care Med 33:S502YS505, 2005.
25. von Gunten S, Yousefi S, Seitz M, Jakob SM, Schaffner T, Seger R, Takala J, Villiger PM, Simon HU: Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 106:1423-1431, 2005.
26. Taneja R, Parodo J, Jia SH, Kapus A, Rotstein OD, Marshall JC: Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity. Crit Care Med 32:1460-1469, 2004.
27. Abraham E: Neutrophils and acute lung injury. Crit Care Med 31:S195YS199, 2003.
28. Simon HU: Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev 193:101-110, 2003.
29. Crocker PR, Paulson JC, Varki A: Siglecs and their roles in the immune system. Nat Rev Immunol 7:255-266, 2007.
30. von Gunten S, Simon HU: Sialic acid binding immunoglobulinYlike lectins may regulate innate immune responses by modulating the life span of granulocytes. FASEB J 20:601-605, 2006.
31. Varki A, Angata T: SiglecsVthe major subfamily of I-type lectins. Glycobiology 16:1RY27R, 2006.
32. von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU: Immunologic and functional evidence for antiYSiglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108:4255-4259, 2006.
33. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
34. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU: Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 8:1124-1132, 2006.
35. Daigle I, Yousefi S, Colonna M, Green DR, Simon HU: Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 8:61-67, 2002.
36. Simon D, von Gunten S, Borelli S, Braathen LR, Simon HU: The interleukin- 13 production by peripheral blood T cells from atopic dermatitis patients does not require CD2 costimulation. Int Arch Allergy Immunol 132:148-155, 2003.
37. Altznauer F, Martinelli S, Yousefi S, et al.: Inflammation-associated cellcycleYindependent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 199:1343-1354, 2004.
38. Daigle I, Simon HU: Critical role for caspases 3 and 8 in neutrophil but not eosinophil apoptosis. Int Arch Allergy Immunol 126:147-156, 2001.
39. Orr SJ, Morgan NM, Buick RJ, Boyd CR, Elliott J, Burrows JF, Jefferies CA, Crocker PR, Johnston JA: SOCS3 targets Siglec 7 for proteosomal degradation and blocks Siglec 7-mediated responses. J Biol Chem 282:3418-3422, 2007.
40. Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA: CD33 responses are blocked by SOCS3 through accelerated proteasomalmediated turnover. Blood 109:1061-1068, 2007.
41. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group: Early goaldirected therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377, 2001.
42. Rivers EP, McIntyre L, Morro DC, Rivers KK: Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 173:1054-1065, 2005.
43. von Gunten S, Simon HU: Sialic acid binding immunoglobulinYlike lectins may regulate innate immune responses by modulating the life span of granulocytes. FASEB J 20:601-605, 2006.
44. von Gunten S, Simon HU: Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 7:453-456, 2008.
45. von Gunten S, Bochner BS: Basic and clinical immunology of Siglecs. Ann N Y Acad Sci 1143:61-82, 2008.
46. Buenz EJ, Howe CL: Appropriate use of intravenous immunoglobulin in neonatal neutropenia. J Perinatol 27:196-197, 2007.
47. von Gunten S, Vogel M, Schaub A, Stadler BM, Miescher S, Crocker PR, Simon HU: Intravenous immunoglobulin preparations contain antiYSiglec-8 autoantibodies. J Allergy Clin Immunol 119:1005-1011, 2007.
48. Nutku E, Hudson SA, Bochner BS: Mechanism of Siglec-8Yinduced human eosinophil apoptosis: role of caspases and mitochondrial injury. Biochem Biophys Res Commun 336:918-924, 2005.
49. Balaian L, Zhong R, Ball ED: The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol 31:363-371, 2003.